The behavior, called nocturia, is a common symptom of numerous conditions like congestive heart failure or bladder disease. The nasal spray, Noctiva, represents the first FDA-approved treatment for this condition, according to the agency.
Thirty minutes before going to bed, adults administer the nasal spray, which increases the kidney’s ability to absorb water and causes less urine production.
Serenity Pharmaceuticals developed the drug, which contains a boxed warning for causing low sodium levels in the blood.
More articles on supply chain:
Lawmakers seek to accelerate approvals with Reauthorized Generic Drug User Fee Act
Physician avoids high cost of EpiPens with homemade device
4 reasons supply chain managers could one day become CEOs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
